Cantor Fitzgerald Comments on TVTX FY2026 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Investment analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Travere Therapeutics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will earn $1.86 per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.08. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The firm had revenue of $81.73 million during the quarter, compared to analyst estimates of $77.44 million. During the same quarter in the prior year, the business posted ($1.76) earnings per share. The company’s quarterly revenue was up 83.3% compared to the same quarter last year.

Several other analysts have also weighed in on TVTX. HC Wainwright initiated coverage on shares of Travere Therapeutics in a report on Wednesday. They set a “buy” rating and a $30.00 price objective for the company. Stifel Nicolaus raised their price objective on shares of Travere Therapeutics from $22.00 to $23.00 and gave the stock a “hold” rating in a report on Friday, May 2nd. Canaccord Genuity Group raised their price objective on shares of Travere Therapeutics from $45.00 to $47.00 and gave the stock a “buy” rating in a report on Thursday, April 10th. Guggenheim reissued a “buy” rating and issued a $47.00 price target on shares of Travere Therapeutics in a report on Monday, April 14th. Finally, Wedbush reissued an “outperform” rating and issued a $30.00 price target on shares of Travere Therapeutics in a report on Friday, May 16th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.14.

Travere Therapeutics Stock Performance

NASDAQ TVTX opened at $14.52 on Wednesday. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -3.54 and a beta of 0.75. The company has a 50 day moving average of $16.87 and a 200-day moving average of $18.59. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. Travere Therapeutics has a 1-year low of $6.80 and a 1-year high of $25.29.

Institutional Investors Weigh In On Travere Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new stake in Travere Therapeutics in the 4th quarter valued at $31,000. Sterling Capital Management LLC increased its stake in shares of Travere Therapeutics by 859.8% during the 4th quarter. Sterling Capital Management LLC now owns 2,361 shares of the company’s stock worth $41,000 after purchasing an additional 2,115 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Travere Therapeutics during the 1st quarter worth about $62,000. KBC Group NV acquired a new position in shares of Travere Therapeutics during the 1st quarter worth about $75,000. Finally, Gen Wealth Partners Inc acquired a new position in shares of Travere Therapeutics during the 4th quarter worth about $73,000.

Insider Transactions at Travere Therapeutics

In other Travere Therapeutics news, CEO Eric M. Dube sold 18,924 shares of Travere Therapeutics stock in a transaction on Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $398,350.20. Following the sale, the chief executive officer now directly owns 419,173 shares in the company, valued at approximately $8,823,591.65. The trade was a 4.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Christopher R. Cline sold 1,784 shares of Travere Therapeutics stock in a transaction on Monday, May 5th. The shares were sold at an average price of $21.05, for a total transaction of $37,553.20. Following the completion of the sale, the chief financial officer now owns 93,126 shares in the company, valued at $1,960,302.30. The trade was a 1.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,527 shares of company stock valued at $473,814 over the last three months. 4.19% of the stock is currently owned by corporate insiders.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.